These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1523283)

  • 1. Are there changes in sensitivity to 5-HT3 receptor ligands following chronic diazepam treatment?
    Andrews N; File SE
    Psychopharmacology (Berl); 1992; 108(3):333-7. PubMed ID: 1523283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced anxiolytic effect of zacopride enantiomers in diazepam-withdrawn rats.
    File SE; Andrews N
    Eur J Pharmacol; 1993 Jun; 237(1):127-30. PubMed ID: 8102974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential modulation of extracellular levels of 5-hydroxytryptamine in the rat frontal cortex by (R)- and (S)-zacopride.
    Barnes NM; Cheng CH; Costall B; Ge J; Naylor RJ
    Br J Pharmacol; 1992 Sep; 107(1):233-9. PubMed ID: 1384906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiles of interaction of R(+)/S(-)-zacopride and anxiolytic agents in a mouse model.
    Barnes NM; Cheng CH; Costall B; Ge J; Kelly ME; Naylor RJ
    Eur J Pharmacol; 1992 Jul; 218(1):91-100. PubMed ID: 1356807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The (S)-isomer of [3H]zacopride labels 5-HT3 receptors with high affinity in rat brain.
    Waeber C; Pinkus LM; Palacios JM
    Eur J Pharmacol; 1990 Jun; 181(3):283-7. PubMed ID: 2384135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethanol- and diazepam-withdrawal hyperlocomotion is not due to 5-HT3 receptor stimulation.
    Mehta AK; Ticku MK
    Pharmacol Biochem Behav; 1993 Jul; 45(3):755-7. PubMed ID: 8332636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of stereoisomers of zacopride to analyze actions of 5-hydroxytryptamine on enteric neurons.
    Wade PR; Mawe GM; Branchek TA; Gershon MD
    Am J Physiol; 1991 Jan; 260(1 Pt 1):G80-90. PubMed ID: 1987811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interaction of R(+)- and S(-)-zacopride with PCPA to modify rodent aversive behaviour.
    Barnes NM; Costall B; Ge J; Kelly ME; Naylor RJ
    Eur J Pharmacol; 1992 Jul; 218(1):15-25. PubMed ID: 1356806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [(125I)iodo-zacopride: new ligand for the study by autoradiography of central 5-HT3 receptors].
    Koscielniak T; Ponchant M; Laporte AM; Guminski Y; Verge D; Hamon M; Gozlan H
    C R Acad Sci III; 1990; 311(6):231-7. PubMed ID: 2121314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The profiles of interaction of yohimbine with anxiolytic and putative anxiolytic agents to modify 5-HT release in the frontal cortex of freely-moving rats.
    Cheng CH; Costall B; Ge J; Naylor RJ
    Br J Pharmacol; 1993 Nov; 110(3):1079-84. PubMed ID: 7507776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the 5-HT3 receptor antagonist properties of ICS 205-930, GR38032F and zacopride.
    Cohen ML; Bloomquist W; Gidda JS; Lacefield W
    J Pharmacol Exp Ther; 1989 Jan; 248(1):197-201. PubMed ID: 2521513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-HT3 receptor agonism may be responsible for the emetic effects of zacopride in the ferret.
    Middlefell VC; Price TL
    Br J Pharmacol; 1991 May; 103(1):1011-2. PubMed ID: 1831684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRL 46470A: a highly potent, selective and long acting 5-HT3 receptor antagonist with anxiolytic-like properties.
    Blackburn TP; Baxter GS; Kennett GA; King FD; Piper DC; Sanger GJ; Thomas DR; Upton N; Wood MD
    Psychopharmacology (Berl); 1993; 110(3):257-64. PubMed ID: 7831418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze.
    Wright IK; Heaton M; Upton N; Marsden CA
    Psychopharmacology (Berl); 1992; 107(2-3):405-14. PubMed ID: 1352058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The differential activities of R (+)- and S(-)-zacopride as 5-HT3 receptor antagonists.
    Barnes JM; Barnes NM; Costall B; Domeney AM; Johnson DN; Kelly ME; Munson HR; Naylor RJ; Young R
    Pharmacol Biochem Behav; 1990 Dec; 37(4):717-27. PubMed ID: 2128757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of potencies of 5-HT3 receptor antagonists at inhibiting aversive behavior to illumination and the von Bezold-Jarisch reflex in the mouse.
    Eglen RM; Lee CH; Khabbaz M; Fontana DJ; Daniels S; Kilfoil T; Wong EH
    Neuropharmacology; 1994 Feb; 33(2):227-34. PubMed ID: 8035908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zacopride: anxiolytic profile in rodent and primate models of anxiety.
    Costall B; Domeney AM; Gerrard PA; Kelly ME; Naylor RJ
    J Pharm Pharmacol; 1988 Apr; 40(4):302-5. PubMed ID: 2900320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-HT3-like receptors in the rat medial prefrontal cortex: an electrophysiological study.
    Ashby CR; Minabe Y; Edwards E; Wang RY
    Brain Res; 1991 Jun; 550(2):181-91. PubMed ID: 1679370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonists at the serotonin-3 receptor can reduce the fear-potentiated startle response in the rat: evidence for different types of anxiolytic activity?
    Nevins ME; Anthony EW
    J Pharmacol Exp Ther; 1994 Jan; 268(1):248-54. PubMed ID: 7905528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The enantiomers of zacopride: an intra-species comparison of their potencies in functional and anxiolytic models.
    Bill DJ; Coleman J; Hallett I; Middlefell VC; Rhodes KF; Fletcher A
    Br J Pharmacol; 1995 Jul; 115(5):775-80. PubMed ID: 8548176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.